Comparative Pharmacology
Head-to-head clinical analysis: QUINACT versus QUINIDINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINACT versus QUINIDINE SULFATE.
QUINACT vs QUINIDINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction. It also inhibits potassium channels, prolonging repolarization, and has vagolytic and negative inotropic effects.
100 mg orally three times daily.
300-600 mg orally every 6-8 hours; maximum 2-4 g/day. Extended-release: 300-600 mg every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Terminal elimination half-life is 6-8 hours in healthy adults; prolonged to 12-18 hours in heart failure, hepatic cirrhosis, or severe renal impairment (CrCl < 10 mL/min).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal excretion of unchanged drug accounts for 10-20% of elimination; hepatic metabolism (hydroxylation and N-oxidation) accounts for 70-80%; about 5% excreted in feces via biliary elimination.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)